Pharmacotherapy for insomnia

Sleep Medicine Clinics

Volumn 5, Issue 4, 2010, Pages 529-539

  Roth, Thomas ^a,b   Roehrs, Timothy ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Insomnia; Pharmacotherapy; Sleep disorders; Therapeutics

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALCOHOL; ALPRAZOLAM; AMITRIPTYLINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CLONAZEPAM; DIPHENHYDRAMINE; DOXEPIN; ESZOPICLONE; FLURAZEPAM; GABAPENTIN; HYPERICUM PERFORATUM EXTRACT; LORAZEPAM; MIRTAZAPINE; OLANZAPINE; OREXIN; QUETIAPINE; RAMELTEON; SEROTONIN 2A AGONIST; SEROTONIN 2C AGONIST; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRIAZOLAM; VALERIAN; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ANTEROGRADE AMNESIA; ANTICHOLINERGIC EFFECT; ANTICHOLINERGIC SYNDROME; AROUSAL; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL; COGNITION; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERANCE; GENERALIZED ANXIETY DISORDER; HEART ARRHYTHMIA; HUMAN; INSOMNIA; INTERNATIONAL CLASSIFICATION OF DISEASES; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEMORY CONSOLIDATION; NONREM SLEEP; OFF LABEL DRUG USE; POLYSOMNOGRAPHY; PREDICTION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; QUESTIONNAIRE; REBOUND; RECEPTOR AFFINITY; RECRUDESCENCE; REM SLEEP; REVIEW; SEDATION; SELF MEDICATION; SEROTONINERGIC NERVE CELL; SLEEP DEPRIVATION; SLEEP DISORDER; SLEEP INDUCTION; SLEEP WAKING CYCLE; SLEEP WALKING; SLOW BRAIN WAVE; SLOW WAVE SLEEP; SUPRACHIASMATIC NUCLEUS; TIME TO MAXIMUM PLASMA CONCENTRATION; VIOLENCE; WITHDRAWAL SYNDROME;

EID: 78649389923     PISSN: 1556407X     EISSN: 15564088     Source Type: Journal    
DOI: 10.1016/j.jsmc.2010.09.002     Document Type: Review

References (70)

1. J.D. Edinger, M.H. Bonnet, and R.R. Bootzin Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine work group Sleep 27 2004 1567 1596
2. World Health Organization International classification of diseases (ICD-10) 1991 World Health Organization Geneva (Switzerland)
3. American Psychiatric Association Diagnostic and statistical manual of mental disorders (DSM-IV-TR) Text Revision 4th edition 2000 American Psychiatric Association Washington, DC
4. T. Roehrs, F. Zorick, and J. Sicklesteel Age-related sleep-wake disorders at a sleep disorder center J Am Geriatr Soc 31 6 1983 364 370
5. A. Rechtschaffen, A. Kales, A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects 1968 Brain Information Service/Brain Research Institute, UCLA Los Angeles (CA)
6. D.J. Greenblatt, L.L. von Moltke, and J.S. Harmatz Kinetic and dynamic interaction study of zolpidem and ketoconazole, itraconazole, and fluconazole Clin Pharmacol Ther 64 6 1998 661 671
7. G.W. Vogel, A. Buffenstein, and K. Minter Drug effects on REM sleep and on endogenous depression Neurosci Biobehav Rev 14 1990 49 63
8. J.K. Walsh, G. Zammit, and P.K. Schweitzer Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia Sleep Med 6 2006 155 161
9. C. Drake, T. Roehrs, and E. Burduvali Effects of rapid versus slow accumulation of eight hours of sleep loss Psychophysiology 38 2001 979 987
10. B.W. Riedel, and K.L. Lichstein Insomnia and daytime functioning Sleep Med Rev 4 3 2000 277 298
11. A. Ancoli-Israel, and T. Roth Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation survey I Sleep 22 2 1999 S347 S353
12. C.H. Bastein, A. Vallieres, and C.M. Morin Validation of the insomnia severity index as an outcome measure for insomnia research Sleep Med 2 2001 297 307
13. National Institutes of Health State of the science conference statement on manifestations and management of chronic insomnia in adults June 13-15, 2005 Sleep 28 9 2005 1049 1057
14. R.Z. Tashjian, R. Banerjee, and M.P. Bradley Zolpidem reduces postoperative pain, fatigue, and narcotic consumption following knee arthroscopy: a prospective randomized placebo-controlled double-blinded study J Knee Surg 19 2 2006 105 111
15. J. Dirks, B.B. Fredensborg, and D. Christensen A randomized study of the effects of single-dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy Anesthesiology 97 3 2002 560 564
16. M. Fava, W.V. McCall, and A. Krystal Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder Biol Psychiatry 59 2006 1052 1060
17. C.L. Drake, H. Scofield, and T. Roth Vulnerability to insomnia: the role of familial aggregation Sleep Med 9 2008 297 302
18. V. Gumenyuk, T. Roth, and J.E. Moran Cortical locations of maximal spindle activity: magnetoencephalography (MEG) study J Sleep Res 18 2 2009 245 253
19. T. Roth, and Ancoli-Israel Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation survey. II Sleep 22 2 1999 S354 S358
20. Gallup Sleep in America 1995 Gallup Princeton (NJ) p. 1-78
21. E.O. Johnson, T. Roehrs, and T. Roth Epidemiology of alcohol and medication as aids to sleep in early adulthood Sleep 21 1998 178 186
22. T. Roehrs, and T. Roth Sleep, sleepiness, sleep disorders and alcohol use and abuse Sleep Med Rev 5 2001 287 297
23. T. Roehrs, K. Papineau, and L. Rosenthal Ethanol as a hypnotic in insomniacs: self administration and effects of sleep and mood Neuropsychopharmacology 20 1999 279 286
24. T. Roehrs, B. Blaisdel, and N. Cruz Tolerance to hypnotic effects of ethanol in insomniacs [abstract] Sleep 27 2004 A52
25. T. Roehrs, E. Hollebeek, and C. Drake Substance use for insomnia in metropolitan Detroit J Psychosom Res 53 2003 571 576
26. K. Rickels, R.J. Morris, and H. Newman Diphenhydramine in insomnia family practice patients: a double-blind study J Clin Pharmacol 23 5-6 1983 234 242
27. G.S. Richardson, T.A. Roehrs, and L. Rosenthal Tolerance to daytime sedative effects of H1 antihistamines J Clin Psychopharmacol 22 2002 511 515
28. N.J. Pearson, L.L. Johnson, and R.L. Nahin Insomnia, trouble sleeping, and complementary and alternative medicine Arch Intern Med 166 2006 1775 1782
29. D.M. Taibi, C.A. Landis, and H. Petry A systematic review of valerian as a sleep aid: safe but not effective Sleep Med Rev 11 2007 209 230
30. Clinical Practice Review Committee American Academy of Sleep Medicine. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence J Clin Sleep Med 1 2005 173 187
31. H. Mohler, J.M. Fritschy, and U. Rudolph A new benzodiazepine pharmacology J Pharmacol Exp Ther 300 2002 2 8
32. W.B. Mendelson, C. Thompson, and T. Franko Adverse reactions to sedative hypnotics: three years' experience Sleep 19 1996 702 706
33. L. Merlotti, T. Roehrs, and G. Koshorek The dose effects of zolpidem on the sleep of healthy normals J Clin Psychopharm 9 1 1989 9 14
34. J.K. Lamphere, T.A. Roehrs, and F.J. Zorick The dose effects of zopiclone Hum Psychopharmacol 4 1989 41 46
35. 2 melatonin receptor agonist indicated for treatment of insomnia J Clin Pharmacol 46 2006 140 148
36. Krystal A, Walsh J, Roth T, et al. Evaluation of the efficacy and safety of eszopiclone over six months of treatment in patients with insomnia [abstract]. Poster presented at sleep 2006. Salt Lake City (UT): Associated Professional Sleep Societies, June 17-26, 2006.
37. J.K. Walsh, A.D. Krystal, and D.A. Amato Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life and work limitations Sleep 30 2007 959 968
38. M.M. Milter, W.F. Seidel, and J. Van Den Hoed Comparative hypnotic effects of flurazepam, triazolam, and placebo: a long-term simultaneous nighttime and daytime study J Clin Psychopharmacol 4 1984 2 13
39. 2 receptor agonist Neuropharmacology 48 2005 301 310
40. T. Roth, C. Stubbs, and J.K. Walsh Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment Sleep 28 3 2005 303 307
41. G. Hajak, A. Rodenbeck, and U. Voderholzer Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study J Clin Psychiatry 62 2001 453 463
42. T. Roth, R. Rogowski, and S. Hull Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia Sleep 30 2007 1555 1561
43. M.A. Carskadon, W.F. Seidel, and D.J. Greenblatt Daytime carryover of triazolam and flurazepam in elderly insomniacs Sleep 5 1982 362 371
44. C.R. Rush, and R.R. Griffiths Zolpidem, triazolam and temazepam: behavioral and subject-rated effects in normal volunteers J Clin Psychopharmacol 16 1996 146 157
45. P. Danjou, P.R. Fruncillo, and P. Worthington A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening Br J Clin Pharmacol 48 1999 367 374
46. T. Roehrs, L. Merlotti, and F. Zorick Sedative, memory and performance effects of hypnotics Psychopharmacology (Berl) 116 1994 130 134
47. T. Roehrs, F. Zorick, and J. Sicklesteel Effects of hypnotics on memory J Clin Psychopharmacol 3 1983 310 313
48. J.F. Green, A. McElholm, and D.J. King A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam Psychopharmacology (Berl) 128 1996 67 73
49. H. Mohler, F. Crestani, and U. Rudolph GABA-A receptor subtypes: a new pharmacology Curr Opin Pharmacol 1 2001 22 25
50. T.A. Roehrs, G. Vogel, and T. Roth Rebound insomnia: its determinants and significant Am J Med 88 1990 43S 46S
51. J.H. Woods, and G. Winger Current benzodiazepine issues Psychopharmacology (Berl) 118 1995 107 115
52. G.D. Mellinger, M.B. Balter, and E.H. Uhlenhuth Insomnia and its treatment Arch Gen Psychiatry 42 1985 225 232
53. T. Roehrs, B. Pedrosi, and L. Rosenthal Hypnotic self administration and dose escalation Psychopharmacology (Berl) 127 1996 150 154
54. T. Roehrs, A. Bonahoom, and B. Pedrosi Nighttime versus daytime hypnotic self-administration Psychopharmacology (Berl) 161 2002 137 142
55. B. Lisko, and A. Pikalov Zaleplon overdose associated with sleepwalking and complex behavior J Am Acad Child Adolesc Psychiatry 43 2004 927 928
56. J.K. Walsh Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine Sleep 27 2004 1441 1442
57. F. Jenck, J.L. Moreau, and V. Mutel Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs Eur J Pharmacol 231 1993 223 229
58. E. Richelson The pharmacology of antidepressants at the synapse: focus on newer compounds J Clin Psychiatry 55 Suppl A 1994 34 39
59. I. Montgomery, I. Oswald, and K. Morgan Trazodone enhances sleep in subjective quality but not in objective duration Br J Clin Pharmacol 16 1983 139 144
60. J.K. Walsh, M. Erman, and C.W. Erwin Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia Hum Psychopharmacol 13 1998 191 198
61. R.N. Golden, K. Dawkins, and L. Nicholas Trazodone and nefazone A. Schatzberg, C. Nemeroff, The American psychiatric textbook of psychopharmacology 2004 American Psychiatric Textbook, Inc Washington, DC 315 325
62. J.L. Levenson Prolonged QT interval after trazodone overdose Am J Psychiatry 156 1999 969 970
63. M. Haria, A. Fitton, and D. McTavish Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders Drugs Aging 4 1994 331 355
64. R.B. Lydiard, D.A. Lankford, and D.J. Seiden Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial J Clin Sleep Med 2 3 2006 309 315
65. T. Roth, A. Lankford, and W.P. Accomando Sleep onset and maintenance in patients with chronic insomnia treated with adipiplon in a cross-over study Sleep 31 Suppl 2008 A40 A41 [abstract]
66. T. Roth, S.G. Hull, and D.A. Lankford Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings Sleep 31 9 2008 1277 1284
67. T. Sakurai, A. Amemiya, and M. Ishii Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior Cell 92 4 1998 573 585
68. L. Lin, J. Faraco, and R. Li The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene Cell 98 3 1999 365 376
69. C. Brisbare-Roch, J. Dingemanse, and R. Kobertsein Promotion of sleep by targeting the orexin system in rats, dogs, and humans Nat Med 13 2 2007 150 155
70. H.P. Landolt, V. Meier, and H.J. Burgess Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra Neuropsychopharmacology 21 3 1999 455 466